NET SALES REPORTS/PAYMENT OF RUNNING ROYALTIES. After the first commercial sale of a LICENSED PRODUCT, and in addition to the reports required under Section 5.02, CYPRESS shall render to OREXIGEN prior to [***] a written account of the NET SALES of LICENSED PRODUCTS made during the prior [***] period ending [***], respectively, and shall simultaneously pay to OREXIGEN the royalties due on such NET SALES in United States dollars. Reports tendered shall include the calculation of royalties by product by country.
Appears in 2 contracts
Sources: License Agreement (Orexigen Therapeutics, Inc.), License Agreement (Orexigen Therapeutics, Inc.)